cancer – Page 11 – Oral Cancer News

Blueberries contain vital polyphenols that could contribute to a decline in obestiy

Source: Medical News Today Last week it was reported that strawberries may help treat throat cancer, now a new study shows how blueberries may aid in curbing obesity. Plant polyphenols have been shown to fight adipogenesis, which is the development of fat cell, and induce lipolysis, which is the breakdown of lipids and fat. The study was done to evaluate whether blueberry polyphenols play a role in adipocyte differentiation, the process in which a relatively unspecialized cell acquires specialized features of an adipocyte, an animal connective tissue cell specialized for the synthesis and storage of fat. Polyphenols occur in all plant foods and contribute to the beneficial health effects of vegetables and fruit. Their contribution to the antioxidant capacity of the human diet is much larger than that of vitamins. The total intake in a person's diet could amount to 1 gram a day, whereas combined intakes of beta-carotene, vitamin C, and vitamin E from food most often is about 100 mg a day. Phenolic acids account for about one third of the total intake of polyphenols in our diet, and flavonoids account for the remaining two thirds. Flavonoids are further subdivided into several categories. Shiwani Moghe, a graduate student at Texas Woman's University said: "The promise is there for blueberries to help reduce adipose tissue from forming in the body I wanted to see if using blueberry polyphenols could inhibit obesity at a molecular stage. We still need to test this dose in humans, to make sure there are [...]

Oral Cancer Foundation News Team - A2011-04-21T13:48:47-07:00April, 2011|Oral Cancer News|

HPV link comes as a shock to male cancer patients

By ANIKA CLARK Stanley Sikora of Fall River and Tom Souza of Swansea clearly remember when they started their battles with cancer — life-changing moments while raking leaves or shaving, when they touched their necks and felt a lump. It's a common experience thanks to a disease that, between the suffering of friends, families and ourselves, has become nearly universal. But then came news neither expected. Tumors from both men tested positive for human papillomavirus, an often sexually transmitted virus that is increasingly being linked to cancers of the head and neck. At Massachusetts General Hospital's Center for Head and Neck Cancers, "it's something that we see practically on a daily basis," said Dr. Lori Wirth, medical director for head and neck oncology, who said in an email that, although there are not-fully-understood co-factors, there's strong data that about 60-65 percent of all cancers of the oropharynx (the rear of the mouth, including the back of the throat, tonsils and the base of the tongue) are HPV-related. "Our awareness that HPV is associated with oropharynx cancers is something that has been emerging over the last 5-10 years," she said. "Ten years ago, we didn't even look for (it)." Upon learning of his HPV diagnosis, "I honestly felt creepy about myself," said Sikora, 59, albeit somewhat reassured when he found out how easily it's transmitted. "Already I was shocked that I got cancer. Now it's from HPV," he said. "So I'm thinking 'I can't be going around telling people I got [...]

Oral Cancer Foundation News Team - A2011-04-04T14:41:03-07:00April, 2011|Oral Cancer News|

We owe it to our sons to protect them against human papilloma virus – the new oral cancer peril

The seemingly unstoppable rise of throat and mouth cancers over the past two decades has left experts baffled and deeply concerned. These are truly horrible diseases. More than 15,000 new patients are diagnosed each year in Britain alone and almost 8,000 die from the most common type, cancer of the oesophagus. Two-thirds of sufferers are men. And those that survive are often left horrifically disfigured by aggressive radiotherapy and surgery. Most worryingly, numbers of new cases have doubled since 1989. We used to think most oral and throat cancers - which also include laryngeal (voice box), tracheal (windpipe) and oropharyngeal (soft-palate) tumours - were due to a lifetime of smoking and heavy alcohol consumption, and only really occurred in old age. But as health messages hit home, numbers of smokers and drinkers dropped, fewer older men and women developed these cancers and a new group of patients - middle-class, middle-aged men who drank moderately and had never smoked - emerged. This was a surprise. Small studies, in which tumours were analysed, indicated a new culprit: the human papilloma virus (HPV), the same virus that we knew was the cause of cervical cancer in women. For years there have been whisperings among oncologists that this could become one of the most significant cancer challenges of the 21st Century. And six weeks ago, evidence published by two American universities showed that these fears were becoming a reality. Researchers found that about half of the male population carried some form of HPV; that every year [...]

Oral Cancer Foundation News Team - A2011-04-04T13:03:49-07:00April, 2011|Oral Cancer News|

Multivitamins Don’t Lower Cancer and Cardiovascular Risk

Source: MedScape Today By: Leigh Krietsch Boerner Will taking multivitamins protect you from dying of cancer or cardiovascular disease? The answer is no, according to new research published online February 22 in the American Journal of Epidemiology. In a study of more than 180,000 people, researchers saw the same number of deaths from cancer and heart disease among multivitamin-takers and those who didn't take the supplements. "People need to understand that just taking these multivitamins is not sufficient to prevent disease," said Dr. Jennifer Hsiang-Ling Lin, of Brigham and Women's Hospital in Boston, who didn't work on the study. Multiple past studies have shown no link between multivitamins and reduced risk of cancer or heart disease. Other recent research couldn't prove that multivitamins protect against diabetes, either. Some small studies in the past have shown that specific vitamins, not multivitamins, may be protective against heart disease or cancer later in life. However these studies looked at undernourished people, not generally healthy adults like the U.S. population, said co-author Dr. Song-Yi Park of the University of Hawaii Cancer Center in Honolulu. On its web site, the U.S. National Institutes of Health advises that doctors should prescribe multivitamins only "for patients who need extra vitamins, who cannot eat enough food to obtain the required vitamins, or who cannot receive the full benefit of the vitamins contained in the food they eat." But more than half of U.S. adults choose to take multivitamins, according to Dr. Lin. Altogether, Dr. Park's team looked at [...]

Oral Cancer Foundation News Team - A2011-04-06T13:46:55-07:00April, 2011|Oral Cancer News|

Fatal adverse events with Bevacizumab

Source: Medscape Today Treatment-Related Mortality With Bevacizumab in Cancer Patients: A Meta-analysis Study Summary Although bevacizumab has been shown to improve survival in patients with a variety of solid tumors when added to conventional chemotherapy, it has also been associated with life-threatening and fatal adverse events (FAEs), including bleeding, thromboembolism, and perforation. This improvement in survival has led to the assumption that FAEs are rare and do not significantly affect patients who are receiving treatment. In this large meta-analysis, Ranpura and colleagues identified 10,217 patients with various solid tumors from 16 randomized studies, as follows: Colorectal cancer (5 studies); Non-small cell lung cancer (4 studies); Breast cancer (3 studies); Renal cell cancer (2 studies); Pancreatic cancer (1 study); and Prostate cancer (1 study). A clear increase in FAEs was evident in patients who received bevacizumab compared with those who received standard chemotherapy alone (2.5% vs 1.7%; relative risk [RR] 1.46; P = .01). This association varied with chemotherapy agents but not with tumor type. In particular, FAEs occurred in patients receiving taxanes or platinum agents (RR 3.49; 3.3% vs 1%) but not with other specific agents. Types of FAEs included bleeding (23.5%), gastrointestinal perforation (7.1%), and pulmonary embolism and stroke (5.1% each). Most fatal bleeding events were pulmonary or gastrointestinal in origin. Viewpoint The benefit of bevacizumab is under increased scrutiny given the latest data in patients with metastatic breast cancer. In this large meta-analysis, Ranpura and colleagues documented a clear increase in the rate of FAEs (2.5%) in patients [...]

Oral Cancer Foundation News Team - A2011-03-03T22:45:53-07:00March, 2011|Oral Cancer News|

Either called “chemobrain” or “chemofog,” the long-term chemotherapy-induced cognitive decline in cancer survivors is real

J Pain Symptom Manage. 2011 Jan 1;41(1):126-139, AA Argyriou, K Assimakopoulos, G Iconomou, F Giannakopoulou, HP Kalofonos Abstract Context: In recent years, there is growing evidence in the medical literature to support an association between administration of commonly used chemotherapeutic agents and an increased risk for cognitive impairment. Objectives: We herein critically summarize data relating to the pathophysiological mechanisms by which chemotherapy may induce cognitive impairment in patients surviving from solid tumors. The clinical and epidemiological characteristics and the proposed management strategies to counter chemotherapy-induced cognitive impairment (CICI) also are presented. Methods: References for this review were identified by searches of PubMed from 1995 until December 2009 with related terms. Results: Both the pathogenetic mechanisms and the overall clinical nature of CICI remain vaguely defined. OCF Findings indicate that CICI is a relatively common event that, in most of the cases, remains under diagnosed, thereby adversely affecting the quality of life of patients with cancer. Effective pharmacological interventions toward the symptomatic or prophylactic management of CICI also are lacking. Conclusion: Either called “chemobrain” or “chemofog,” the long-term CICI in cancer survivors is real. The need for multidisciplinary care interventions toward a timely diagnosis and management of CICI is clearly warranted.

Oral Cancer Foundation News Team - A2011-02-19T10:03:29-07:00February, 2011|Oral Cancer News|

Global cancer statistics

Source: HighWire, Stanford University The global burden of cancer continues to increase largely because of the aging and growth of the world population alongside an increasing adoption of cancer-causing behaviors, particularly smoking, in economically developing countries. Based on the GLOBOCAN 2008 estimates, about 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008; of these, 56% of the cases and 64% of the deaths occurred in the economically developing world. Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females, accounting for 23% of the total cancer cases and 14% of the cancer deaths. Lung cancer is the leading cancer site in males, comprising 17% of the total new cancer cases and 23% of the total cancer deaths. Breast cancer is now also the leading cause of cancer death among females in economically developing countries, a shift from the previous decade during which the most common cause of cancer death was cervical cancer. Further, the mortality burden for lung cancer among females in developing countries is as high as the burden for cervical cancer, with each accounting for 11% of the total female cancer deaths. OCF Although overall cancer incidence rates in the developing world are half those seen in the developed world in both sexes, the overall cancer mortality rates are generally similar. Cancer survival tends to be poorer in developing countries, most likely because of a combination of a late stage at diagnosis and limited [...]

Oral Cancer Foundation News Team - A2011-02-16T11:19:17-07:00February, 2011|Oral Cancer News|

Tobacco industry adapts to world of fewer smokers

Source: The Tennessean Author: Anita Wadhwani By any name or variety you choose — call it snuff, dip, chew or plug — smokeless tobacco is making a comeback, and Tennessee farmers, factory workers and consumers are playing a major role in the renewed buzz. Farmers here and in Kentucky who once made a good living off raising burley tobacco for cigarettes have had to eliminate 40 percent of acreage devoted to that crop as demand has declined, while farmers who cultivate the dark tobacco used for chewing have been able to expand their fields by 22 percent in three years. Now, the massive marketing muscle of the nation's biggest tobacco companies — Altria Group and its subsidiary Philip Morris USA, which owns the 100-year-old U.S. Smokeless Tobacco Co. factory within view of the state Capitol, and R.J. Reynolds, which runs its smokeless operations out of a Memphis factory — are battling for market dominance. Together, the two manufacturers already control 90 percent of the American smokeless tobacco sector with brands such as U.S. Smokeless' Skoal and R.J. Reynolds' Kodiak. They're competing with new fruit- and mint-flavored products (some packaged to look like miniature cigarette packs) to attract a new generation of consumers and entice ex-smokers looking for nicotine- infused alternatives. Former cigarette smokers like Dave Kenner, 31, a construction worker making a pit stop at a West Nashville convenience store last week, said he switched to Red Seal Wintergreen smokeless because heavily taxed cigarettes cost too much — nearly $300 [...]

Charlotte Parker2011-02-04T12:24:02-07:00February, 2011|Oral Cancer News|

Oncologists must discuss all options in advanced cancer: ASCO policy

Source: MedScape.com By: Zosia Chustecka January 28, 2011 — A new policy statement from the American Society of Clinical Oncology (ASCO) aims to improve communication with, and decision making for, patients with advanced cancer (defined as incurable disease). It calls for a change in paradigm for advanced cancer care and a new approach in which all available treatment options are discussed from the very beginning. The statement was published online on January 24 in the Journal of Clinical Oncology. "While improving survival is the oncologist's primary goal, helping individuals live their final days in comfort and dignity is one of the most important responsibilities of our profession," ASCO president George Sledge, MD, said in a statement. "Oncologists must lead the way in discussing the full range of curative and palliative therapies to ensure that patients' choices are honored," he said. New Paradigm of Care This new approach "requires stepping back from the paradigm of applying one line of therapy after the other and focusing primarily on disease-directed interventions," say the authors, comprised of a panel of oncologists and specialists in palliative care. "Instead, we need to move toward developing a treatment plan that is consistent with evidence-based options (including disease-directed and palliative care), and the patients' informed preferences for how we pursue and balance these options throughout the course of illness," they add. Conversations about all of the options that are available must be started earlier, and they must be more thorough, the panel insists. "These conversations should be going on [...]

Oral Cancer Foundation News Team - A2011-01-29T11:01:08-07:00January, 2011|Oral Cancer News|

Diagnostic chip may help hearts, cut costs

Souce: HealthCanal.com By: Mike Williams Rice University technology in human trials to spot cardiac disease, cancer, drug abuse Heart disease is a silent killer, but new microchip technology from Rice University is expected to advance the art of diagnosis. During National Heart Health Month, Rice Professor John McDevitt will discuss the potential of this technology to detect cardiac disease early at the annual meeting of the American Association for the Advancement of Science (AAAS) in Washington, D.C., Feb. 17-21. Cardiac disease is the focus of one of six ongoing major clinical trials of Rice's programmable bio-nano-chips (PBNCs). PBNCs combine microfluidics, nanotechnology, advanced optics and electronics to enable quick, painless diagnostic tests for a wide range of diseases at minimal cost. Current clinical trials employ PBNCs to test more than 4,000 patients for signs of heart disease, ovarian cancer, prostate cancer, oral cancer and drug abuse. Versions to test for HIV/AIDS and other diseases are also in development. "Too often, the first time people know they're suffering from heart disease is when it kills them," said McDevitt, Rice's Brown-Wiess Professor of Chemistry and Bioengineering, who will participate in a global health seminar at AAAS. "With this test, we expect to save lives and dramatically cut the recovery time and cost of caring for those who suffer from heart ailments," said McDevitt, a pioneer in the creation of microfluidic devices for biomedical testing. He anticipates the PBNCs, when manufactured in bulk, will cost only a few dollars each. PBNCs analyze a patient's [...]

Oral Cancer Foundation News Team - A2011-01-27T13:47:30-07:00January, 2011|Oral Cancer News|